Medical therapy for advanced non-small-cell lung cancer

Abstract

Abstract: The 5-year survival rate of advanced non-small cell lung cancer(NSCLC), is less than 5%. Clinically chemotherapy and targeted therapy are currently used in NSCLC treatment. In recent years, with the emergence of molecular targeted therapy drugs, such as human epidermal growth factor tyrosine kinase inhibitors, angiogenesis inhibitors, the anti-tumor monoclonal antibodies and multi-target drugs, the overall survival of advanced non-small cell lung cancer had been extended significantly and the quality of patient’s life improved remarkably. Molecular targeted therapy has become the most promising treatment and can significantly improve the prognosis of advanced NSCLC.

ZHANG Shu-cai,ZHANG Hui. Medical therapy for advanced non-small-cell lung cancer[J]. Journal of Tuberculosis and Lung Health , 2012, 1(1): 15-21.

References

[1] Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol, 2007,18(3):581-592.
[2] Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009. CA Cancer J Clin,2009,59(4):225-249.
[3] NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systematic review and Meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol,2008,26(28):4617-4625.
[4] Baggstrom MQ, Stinchcombe TE, Fried DB, et al. Third-gene-ration chemotherapy agents in the treatment of advanced non-small cell lung cancer:a Meta-analysis. J Thorac Oncol, 2007,2(9):845-853.
[5] Scagliotti GV, Parikh P, von Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-native patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008,26(21):3543-3551.
[6] Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase Ⅲ trial of paclitaxel plus carboplatin versus vinorelbine plus cisp-latin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol,2001,19(13):3210-3218.
[7] Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002,346(2):92-98.
[8] Le Chvalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other pla-tinum containing regimen in advanced non-small-cell lung can-cer: a Meta-analysis of survival outcomes. Lung Cancer,2005,47(1):69-80.
[9] Ardizzoni A, Boni L, Tiseo M, et al.Cisplatin-versus carbop-latin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data Meta-analysis. J Natl Cancer Inst, 2007,99(11):847-857.
[10] Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.J Clin Oncol,2004, 22(19):3852-3859.
[11] Lilenbaum R, Zukin M, Pereira JR, et al. A randomized phase Ⅲ trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2(Abstract 7506)[J/OL].J Clin Oncol,2012,30(Suppl) [2012-07-10].http://www.asco.org.
[12] NSCLC Meta-Analyses Collaborative Group.Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and Meta-analysis of individual patient data from 16 randomized controlled trials.J CIin Oncol,2008,26(28):4617-4625.
[13] Koutsopoulos AV, Mavroudis D, Dambaki KI, et al. Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer,2007,57(2):193-200.
[14] Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer,2005,5(5):341-354.
[15] Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med,2009,361(10):947-957.
[16] Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol,2010,11(2):121-128.
[17] Maemondo M,Inoue A,Kobayashi K,et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med,2010, 362(25):2380-2388.
[18] Mitsudomi T, Morita S, Yatabe Y, et al. Updated overall survival results of WJTOG 3405, a randomized phase Ⅲ trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)(Abstract 7521) [J/OL]. J Clin Oncol, 2012,30(Suppl) [2012-07-10].http://www.asco.org.
[19] Zhou C, Wu YL, Chen G, et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase Ⅲ, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC)(Abstract 7520) [J/OL]. J Clin Oncol, 2011,29 (Suppl) [2012-07-10].http://www.asco.org.
[20] Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy(LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 2012,13(5):528-538.
[21] Yang J. Afatinib prolongs progression-free survival in NSCLC(Abstract LBA7500) [J/OL]. J Clin Oncol, 2012,30(Suppl) [2012-07-10].http://www.asco.org.
[22] Mok T, Wu YL, Thongprasert S, et al. A randomized placebo-controlled phase Ⅲ study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-Ⅱ(Abstract 7519) [J/OL]. J Clin Oncol,2012,30(Suppl) [2012-07-10].http://www.asco.org.
[23] Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer(FLEX): an open-label randomized phase Ⅲ trial. Lancet,2009,373(9674):1525-1531.
[24] Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol,2009,27(36):6251-6266.
[25] Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med,2006,355(24):2542-2550.
[26] Reck M, von Pawel J, Zatloukal P, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol,2009,27(8):1227-1234.
[27] Besse B, Lasserre SF, Comton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res, 2010,16(1):269-278.
[28] Scagliotti G,Novello S,von Pawel J,et al. Phase Ⅲ study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol,2010, 28(11):1835-1842.
[29] Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet,2009,374(9699):1432-1440.
[30] Paz-Ares L, Marinis FD, Dediu M, et al. Final overall survi-val (OS) results of the phase Ⅲ study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)(Abstract LBA7507) [J/OL].J Clin Oncol,2012,30(Suppl) [2012-07-10].http://www.asco.org.
[31] Belani CP, Waterhouse DM, Ghazal H, et al. Phase Ⅲ study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small-cell lung cancer (NSCLC) (Abstract 7506)[J/OL].J Clin Oncol,2010,28(Suppl). [2012-07-10].http://www.asco.org.
[32] Soon YY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and Meta-analysis of randomized trials.J Clin Oncol,2009,27(20):3277-3283.
[33] Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol,2010, 11(6):521-529.
[34] Miller V, O’Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase Ⅲb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small-cell lung cancer (NSCLC)(Abtract 8002) [J/OL]. J Clin Oncol, 2009, 27(15 Suppl) [2012-07-10].http://www.asco.org.
[35] Gerald SB, Vittorio G, Frank M, et al. Phase Ⅱ study of pemetrexed (Pem) and cisplatin (Cis) plus cetuximab (Cet) followed by Pem and Cet maintenance therapy in patients (Pts) with advanced nonsquamous non-small cell lung cancer (NSCLC)(Abstract 7554) [J/OL]. J Clin Oncol, 2012,30(Suppl) [2012-07-10].http://www.asco.org.
[36] Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004, 22(9):1589-1597.
[37] Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life ana-lysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol,2006,24(24):3831-3837.
[38] Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet,2005,366(9496):1527-1537.
[39] Sun Y,Shi Y,Zhang L,et al.Final overall survival and updated biomarker analysis results from the randomized phase Ⅲ ICOGEN trial(Abstract 7559)[J/OL].J Clin Oncol,2012,30(Suppl) [2012-07-10].http://www.asco.org.
[40] Garassino MC, Martelli O, Bettini A, et al.A phase Ⅲ trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR(Abstract LBA7501)[J/OL].J Clin Oncol,2012,30(Suppl) [2012-07-10].http://www.asco.org.
[41] Kim ES, Neubauer MA, Cohn AL, et al. Randomized phase Ⅲ study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy(Abstract 7502)[J/OL].J Clin Oncol,2012,30(Suppl) [2012-07-10].http://www.asco.org.
[42] Janne PA, Shaw AT, Pereira JR, et al. Phase Ⅱ double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC)(Abstract 7503) [J/OL]. J Clin Oncol, 2012,30(Suppl) [2012-07-10].http://www.asco.org.
[43] Bang Y,Kwak EL,Shaw AT,et al.Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer(NSCLC)(Abstract 3)[J/OL].J Clin Oncol,2010,28(Suppl):S18[2012-07-10].http://www.asco.org.
[44] Schuler MH, Planchard D, Yang JC, et al. Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy(Abstract 7557)[J/OL]. J Clin Oncol, 2012,30(Suppl) [2012-07-10].http://www.asco.org.
[45] Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase Ⅱ study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC(Abstract 7505)[J/OL].J Clin Oncol,2011,29(Suppl) [2012-07-10].http://www.asco.org.
[46] Park K, Tsai CM, Ahn MJ, et al. Phase Ⅱ study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)(Abstract TPS7614)[J/OL].J Clin Oncol,2012,30(Suppl) [2012-07-10].http://www.asco.org.
[47] Boyer MJ, Janne PA., Mok T, et al. Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase Ⅲ study(Abstract TPS7615)[J/OL]. J Clin Oncol, 2012,30(Suppl) [2012-07-10].http://www.asco.org.